HUTCHMED (China) Limited ADR (HCM)
NASDAQ: HCMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 14.28 0.00%
HCM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.48B
- P/E (TTM)
- 142.80
- Forward P/E
- 55.09
- EPS (TTM)
- $0.10
- Dividend yield
- None
- 52-week range
- 9.77 – 16.40
- Day range
- 14.06 – 14.35
- Volume / Avg
- 58.03K / 67.45K
- Beta
- —
- Shares outstanding
- 173.81M
52-week range
HCM stock today
On Oct 7, HCM ended the session at $14.28, shedding $0.32 (2.19%), versus the S&P 500's 0.22% decline. At this level, HCM sits in the middle of its 52-week range of $9.77 to $16.40: 12.9% below the high, set on Oct 8, 2025 and 46.2% above the low. HCM is up 7.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 10.6%.
HUTCHMED (China) trades at 142.8x its trailing twelve-month earnings per share of $0.10. Its forward P/E of 55.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About HUTCHMED (China)
Company profileHUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Chig Fung Cheng BEc, CA
- Headquarters
- Hong Kong
- Employees
- 1,790
- IPO year
- 2016
- Website
- hutch-med.com
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$22.01+54.13%
- Strong buy 2
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
HCM news
All HCM newsHUTCHMED (China) peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. | 22.13 | -0.63% | $2.59B | vs HCM |
| SUPNSupernus Pharmaceuticals Inc. | 43.05 | +0.51% | $2.51B | vs HCM |
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs HCM |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs HCM |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs HCM |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs HCM |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs HCM |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs HCM |
Indexes, lists and sector
HUTCHMED (China) stock FAQ
What is HUTCHMED (China)'s stock price today?
HCM last traded at $14.28 as of Oct 7, 4:00 PM EDT, down 2.19% on the day. Prices are delayed at least 15 minutes.
What is HCM's P/E ratio?
HCM trades at a trailing P/E ratio of 142.80 and a forward P/E of 55.09.
Who is HUTCHMED (China)'s CEO?
Mr. Chig Fung Cheng BEc, CA is the chief executive officer of HUTCHMED (China) Limited ADR, which has about 1,790 employees.
What is the HCM 52-week high?
The 52-week high for HCM is $16.40 and the 52-week low is $9.77. The stock is currently 12.9% below its high.